Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NG11-2 for Radiation-Induced Oral Mucositis in Head & Neck Cancer
NCT06669390Phase 1Completed
- Sponsor
- VasoDynamics
- Start
- May 2023
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NG11-2 in oral mucositis (OM), sponsored by VasoDynamics. Primary endpoints: Dose Limiting Toxicities and Serious Adverse Events. Started May 2023; status: completed.
02
Drugs
NG11-2
03
Conditions
oral mucositis (OM)
Beyond the preview
Go deeper on NCT06669390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06669390.